Literature DB >> 2921312

Estrogen replacement decreases the set point of parathyroid hormone stimulation by calcium in normal postmenopausal women.

A Boucher1, P D'Amour, L Hamel, P Fugère, M Gascon-Barré, R Lepage, L G Ste-Marie.   

Abstract

Estrogens decrease serum total and ionized calcium (Ca) concentrations in postmenopausal women with or without primary hyperparathyroidism, but cause little or no increase in serum PTH suggesting a modification of the relationship between the two. In order to define this relationship, we studied the effect of conjugated estrogens on total and ionized serum Ca and serum PTH concentrations in five normal postmenopausal women, before and after 3, 11, and 23 weeks of therapy. Dynamic tests of parathyroid gland function, based on 2-h iv infusions of CaCl2 and NaEDTA, were performed at each time. Total and ionized serum Ca and carboxylterminal PTH were measured every 15 min during the infusions, and parathyroid function was evaluated by a nonlinear 4-parameter mathematical model. Estrogen therapy caused decreases in serum total [2.36 +/- 0.04 (SD) mmol/L, baseline vs. 2.19 +/- 0.05 mmol/L, 23 weeks, P less than 0.005) and ionized calcium (1.27 +/- 0.01 mmol/L, baseline vs. 1.21 +/- 0.02 mmol/L, 23 weeks, P less than 0.005]; the decreases were evident at 3 weeks and persisted for the duration of the study. Serum PTH concentrations did not change (8.94 +/- 1.84 pmol/L, baseline vs. 8.98 +/- 2.38 pmol/L, 23 weeks). Three parameters of the parathyroid function, the maximal response to hypocalcemic stimulation, the nonsuppressible fraction of circulating PTH, and the slope of PTH on calcium at the set point were not affected by estrogen treatment. The fourth parameter, the set point of PTH stimulation by serum total calcium (2.16 +/- 0.04 mmol/L, baseline vs. 1.97 +/- 0.07 mmol/L, 23 weeks, P less than 0.0166) or by serum ionized Ca (1.19 +/- 0.04 mmol/L, baseline vs. 1.12 +/- 0.03 mmol/L, 23 weeks, P less than 0.01), was decreased by estrogen treatment. This was evident at the earliest time point studied and persisted thereafter. The decrease in ionized Ca set point only explained 40% of the decrease in total calcium set point, the remaining 60% being related to hemodilution of plasma protein during therapy. We conclude that estrogen replacement can influence parathyroid function in postmenopausal women by resetting the set point of PTH stimulation by ionized Ca. This in turn could contribute to the estrogen-induced changes in their Ca balance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2921312     DOI: 10.1210/jcem-68-4-831

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

1.  Demographic, dietary, and serum factors and parathyroid hormone in the National Health and Nutrition Examination Survey.

Authors:  J M Paik; W R Farwell; E N Taylor
Journal:  Osteoporos Int       Date:  2011-09-20       Impact factor: 4.507

2.  Exercise frequency and calcium intake predict 4-year bone changes in postmenopausal women.

Authors:  Ellen C Cussler; Scott B Going; Linda B Houtkooper; Vanessa A Stanford; Robert M Blew; Hilary G Flint-Wagner; Lauve L Metcalfe; Ji-Eun Choi; Timothy G Lohman
Journal:  Osteoporos Int       Date:  2005-11-10       Impact factor: 4.507

3.  The effects of menopause and estrogen replacement therapy on the renal handling of calcium.

Authors:  S Adami; D Gatti; F Bertoldo; M Rossini; A Fratta-Pasini; N Zamberlan; E Facci; V Lo Cascio
Journal:  Osteoporos Int       Date:  1992-07       Impact factor: 4.507

Review 4.  Calcium supplementation of the diet: justified by present evidence.

Authors:  B E Nordin; R P Heaney
Journal:  BMJ       Date:  1990-04-21

5.  The effects of brisk walking on markers of bone and calcium metabolism in postmenopausal women.

Authors:  K Thorsen; A Kristoffersson; R Lorentzon
Journal:  Calcif Tissue Int       Date:  1996-04       Impact factor: 4.333

6.  Severe obesity is associated with symptomatic presentation, higher parathyroid hormone levels, and increased gland weight in primary hyperparathyroidism.

Authors:  Mohamed Abdelgadir Adam; Brian R Untch; Melissa E Danko; Sandra Stinnett; Darshana Dixit; James Koh; Jeffrey R Marks; John A Olson
Journal:  J Clin Endocrinol Metab       Date:  2010-08-04       Impact factor: 5.958

7.  The effects of salmon calcitonin-induced hypocalcemia on bone metabolism in ovariectomized rats.

Authors:  Rachel A Davey; Howard A Morris
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

8.  Does estrogen replacement therapy influence parathyroid hormone responsiveness to exogenous hypercalcemia in postmenopausal women?

Authors:  I Zofková; S Röjdmark; R L Kancheva
Journal:  J Endocrinol Invest       Date:  1993-05       Impact factor: 4.256

9.  Effects of salmon calcitonin on the bone loss induced by ovariectomy.

Authors:  G F Mazzuoli; S Tabolli; F Bigi; C Valtorta; S Minisola; D Diacinti; L Scarnecchia; G Bianchi; M Piolini; S Dell'Acqua
Journal:  Calcif Tissue Int       Date:  1990-10       Impact factor: 4.333

10.  Biochemical short-term changes produced by hormonal replacement therapy.

Authors:  J F Aloia; A Vaswani; J K Yeh; D M McGowan; P Ross
Journal:  J Endocrinol Invest       Date:  1991-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.